GLP1R and type 2 diabetes mellitus: Nonetheless, the proportion of renin-angiotensin system antagonists and beta-blockers was similar in patients with and without T2DM, almost all T2DM subjects were on metformin and none of them was receiving SGLT-2 inhibitors or glucagon-like peptide 1 receptor agonists.